Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients With Major Depressive Disorder

NCT00415142 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00415142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00415142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients With Major Depressive Disorder
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
February 29, 2008
Enrollment
393 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder